Millennium Management’s Intellia Therapeutics NTLA Stock Holding History

Millennium Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-62,700	Closed	-$2.19M	–	6695
2022 Q4	$2.19M	Buy	+62,700	New	+$2.98M	﹤0.01%	3489
2022 Q3	–	Sell	-10,500	Closed	-$543K	–	7361
2022 Q2	$543K	Buy	+10,500	New	+$533K	﹤0.01%	4883
2021 Q3	–	Sell	-65,000	Closed	-$10.5M	–	7098
2021 Q2	$10.5M	Sell	65,000 -3,500	-5%	-$273K	0.01%	1834
2021 Q1	$5.5M	Buy	68,500 +58,500	+585%	+$3.93M	﹤0.01%	2470
2020 Q4	$544K	Buy	+10,000	New	+$363K	﹤0.01%	4126

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management's NTLA Position: Q1 2026 in Review

Millennium Management reduced its Intellia Therapeutics (NTLA) stake by 44% in Q1 2026, selling an estimated $712K and leaving 70,559 shares worth $905K. The position accounts for ﹤0.01% of the portfolio, ranked #4464.

Millennium Management first reported a position in NTLA in Q3 2016 and has held it in 33 quarters since. The position peaked at $36.4M in Q1 2022. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Millennium Management held 70,559 shares of Intellia Therapeutics worth $905K as of Q1 2026.
Millennium Management sold 55,867 Intellia Therapeutics shares in Q1 2026, an estimated $712K.
Intellia Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4464 holding.
Millennium Management first reported a position in Intellia Therapeutics in Q3 2016 and has held it in 33 quarters since.
Millennium Management's Intellia Therapeutics position peaked at $36.4M in Q1 2022.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.